Back to News
Market Impact: 0.3
SeaStar Reports Higher Survival In QUELIMMUNE Pediatric Kidney Injury Analysis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
SeaStar Medical said critically ill pediatric patients with sepsis-associated acute kidney injury who received QUELIMMUNE (SCD-PED) had significantly higher survival rates than a historical comparison group in the primary analysis. The article excerpt provides no survival figures or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ICU0.65
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas